NCT05702424 - Evaluation of IGM-7354 in Adults With Relapsed and/or Refractory Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 10, 2023

Primary Completion Date

May 31, 2024

Study Completion Date

May 31, 2024

Conditions

Solid Tumor

Interventions

DRUG

IGM-7354

IGM-7354 is a PD-L1-targeted cytokine that is designed to regulate T and natural killer cell activation, proliferation and promote their anti-tumor effects

Trial Locations (5)

28078

Carolina Biooncology Institute, Huntersville

34232

Florida Cancer Specialists & Research Institute, Sarasota

73019

Oklahoma University, Norman

78229

START South Texas Accelerated Research Therapeutics, San Antonio

06520

Yale University, New Haven